View in EDS

Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degeneration.

Saved in:
Bibliographic Details
Title: Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degeneration.
Authors: Lanzetta P; Department of Medicine-Ophthalmology, University of Udine, and Istituto Europeo di Microchirurgia Oculare-IEMO, Udine-Milan, Italy., Korobelnik JF; CHU Bordeaux, Service d'Ophtalmologie, Bordeaux, France.; University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR1219, Bordeaux, France., Heier JS; Ophthalmic Consultants of Boston, Boston, MA, USA., Leal S; Bayer Consumer Care AG, Basel, Switzerland., Holz FG; Department of Ophthalmology, University of Bonn, Bonn, Germany., Clark WL; Palmetto Retina Center, West Columbia, SC, USA., Eichenbaum D; Retina Vitreous Associates of Florida, Tampa, FL, USA., Iida T; Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan., Sun X; Shanghai General Hospital, Shanghai, China., Berliner AJ; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Schulze A; Bayer AG, Berlin, Germany., Schmelter T; Bayer AG, Berlin, Germany., Schmidt-Ott U; Bayer AG, Berlin, Germany., Zhang X; Bayer Consumer Care AG, Basel, Switzerland., Vitti R; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Chu KW; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Reed K; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Rao R; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Bhore R; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Cheng Y; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Wong TY; Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, and Tsinghua Medicine, Tsinghua University, Beijing, China.
Source: Therapeutic advances in ophthalmology [Ther Adv Ophthalmol] 2025 Aug 18; Vol. 17, pp. 25158414251356388. Date of Electronic Publication: 2025 Aug 18 (Print Publication: 2025).
Publication Type: Journal Article; Review
Journal Info: Publisher: Sage Publications Ltd Country of Publication: United States NLM ID: 101728805 Publication Model: eCollection Cited Medium: Internet ISSN: 2515-8414 (Electronic) Linking ISSN: 25158414 NLM ISO Abbreviation: Ther Adv Ophthalmol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40837592
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degeneration.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lanzetta+P%22">Lanzetta P</searchLink>; Department of Medicine-Ophthalmology, University of Udine, and Istituto Europeo di Microchirurgia Oculare-IEMO, Udine-Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Korobelnik+JF%22">Korobelnik JF</searchLink>; CHU Bordeaux, Service d'Ophtalmologie, Bordeaux, France.; University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR1219, Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Heier+JS%22">Heier JS</searchLink>; Ophthalmic Consultants of Boston, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Leal+S%22">Leal S</searchLink>; Bayer Consumer Care AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Holz+FG%22">Holz FG</searchLink>; Department of Ophthalmology, University of Bonn, Bonn, Germany.<br /><searchLink fieldCode="AU" term="%22Clark+WL%22">Clark WL</searchLink>; Palmetto Retina Center, West Columbia, SC, USA.<br /><searchLink fieldCode="AU" term="%22Eichenbaum+D%22">Eichenbaum D</searchLink>; Retina Vitreous Associates of Florida, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Iida+T%22">Iida T</searchLink>; Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Sun+X%22">Sun X</searchLink>; Shanghai General Hospital, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Berliner+AJ%22">Berliner AJ</searchLink>; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Schulze+A%22">Schulze A</searchLink>; Bayer AG, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Schmelter+T%22">Schmelter T</searchLink>; Bayer AG, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Schmidt-Ott+U%22">Schmidt-Ott U</searchLink>; Bayer AG, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Zhang+X%22">Zhang X</searchLink>; Bayer Consumer Care AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Vitti+R%22">Vitti R</searchLink>; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Chu+KW%22">Chu KW</searchLink>; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Reed+K%22">Reed K</searchLink>; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Rao+R%22">Rao R</searchLink>; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Bhore+R%22">Bhore R</searchLink>; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Cheng+Y%22">Cheng Y</searchLink>; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Wong+TY%22">Wong TY</searchLink>; Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, and Tsinghua Medicine, Tsinghua University, Beijing, China.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101728805%22">Therapeutic advances in ophthalmology</searchLink> [Ther Adv Ophthalmol] 2025 Aug 18; Vol. 17, pp. 25158414251356388. <i>Date of Electronic Publication: </i>2025 Aug 18 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Review
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Sage+Publications+Ltd%22">Sage Publications Ltd </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101728805 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2515-8414 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2225158414%22">25158414 </searchLink><i>NLM ISO Abbreviation: </i>Ther Adv Ophthalmol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40837592
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1177/25158414251356388
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 25158414251356388
    Titles:
      – TitleFull: Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degeneration.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lanzetta P
      – PersonEntity:
          Name:
            NameFull: Korobelnik JF
      – PersonEntity:
          Name:
            NameFull: Heier JS
      – PersonEntity:
          Name:
            NameFull: Leal S
      – PersonEntity:
          Name:
            NameFull: Holz FG
      – PersonEntity:
          Name:
            NameFull: Clark WL
      – PersonEntity:
          Name:
            NameFull: Eichenbaum D
      – PersonEntity:
          Name:
            NameFull: Iida T
      – PersonEntity:
          Name:
            NameFull: Sun X
      – PersonEntity:
          Name:
            NameFull: Berliner AJ
      – PersonEntity:
          Name:
            NameFull: Schulze A
      – PersonEntity:
          Name:
            NameFull: Schmelter T
      – PersonEntity:
          Name:
            NameFull: Schmidt-Ott U
      – PersonEntity:
          Name:
            NameFull: Zhang X
      – PersonEntity:
          Name:
            NameFull: Vitti R
      – PersonEntity:
          Name:
            NameFull: Chu KW
      – PersonEntity:
          Name:
            NameFull: Reed K
      – PersonEntity:
          Name:
            NameFull: Rao R
      – PersonEntity:
          Name:
            NameFull: Bhore R
      – PersonEntity:
          Name:
            NameFull: Cheng Y
      – PersonEntity:
          Name:
            NameFull: Wong TY
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 18
              M: 08
              Text: 2025 Aug 18
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2515-8414
          Numbering:
            – Type: volume
              Value: 17
          Titles:
            – TitleFull: Therapeutic advances in ophthalmology
              Type: main
ResultId 1